Agilent Technologies, Inc. (A) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2025-12-22

Business type: Franchise

How it makes money

Agilent generated $6,948 million in net revenue in 2025, up 7 percent when compared to 2024.

Agilent operates across three primary reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment supplies liquid chromatography, mass spectrometry, pathology tissue staining, cell analysis platforms, genomics microarrays, and contract development and manufacturing organization (CDMO) services for synthesized oligonucleotide active pharmaceutical ingredients.

Agilent CrossLab provides services, software, and consumables spanning the entire analytical laboratory. Its portfolio includes gas and liquid chromatography columns, sample preparation products, OpenLab informatics software, and laboratory automation equipment.

The Applied Markets segment supplies gas chromatography, spectrometry, and vacuum solutions used to test food safety, water quality, environmental pollutants, and chemical purity. CrossLab revenue is largely recurring, supported by direct sales, e-commerce, and regional service networks.

What protects it: the moat

Agilent protects revenue stability through recurring service and consumables sales that are less susceptible to market seasonality than hardware sales.

Agilent insulates its services and supplies business from capital spending downturns by offering vendor-neutral consumables and lab maintenance. Most of the CrossLab portfolio can support laboratory equipment regardless of which manufacturer built the original instrument.

By embedding its OpenLab software, tissue diagnostic stains, companion diagnostics, and proprietary instrument fittings directly into routine laboratory workflows, Agilent establishes ongoing operational reliance across pharmaceutical, clinical, and industrial testing environments.

What growth costs

Revenue from the BIOVECTRA acquisition contributed approximately 5 percentage points to segment growth in 2025.

To expand its specialized CDMO offerings and clinical-to-commercial scale production of active pharmaceutical ingredients, Agilent completed the acquisition of BIOVECTRA. The addition expanded capabilities in microbial fermentation, bioreagents, peptide purification, and biomanufacturing across nucleic acid modalities.

To sustain long-term growth, Agilent maintains active research and development programs alongside global manufacturing networks across North America, Europe, and Asia-Pacific. Operational expansion requires ongoing investments in regulatory clearance for FDA-registered facilities, supply chain optimization, and specialized instrument assembly capacity.

What could damage it

Drug program cancellations following clinical trial failures threaten collaborative companion diagnostics development and contract drug manufacturing revenues.

Agilent partners directly with biopharmaceutical companies to co-develop targeted tissue companion diagnostics and synthesize specialized oligonucleotide active pharmaceutical ingredients for novel clinical therapeutics. If client drug candidates fail during clinical trials, projects get terminated abruptly, impairing associated assay development and long-term CDMO production agreements.

About Agilent Technologies, Inc.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

More on A

Other companies in Diagnostics & Research